Davies Collison Cave boasts an industry leading team that head professional bodies, provide high-level government advice and have proven records as respected advocates.
B.Sc.(Hons.), PhD., MIP Law , Patent and Trade Mark Attorney
Alex has extensive experience in the preparation and prosecution of patent applications in a wide range of biotechnology-related disciplines, including molecular biology, cell biology, immunology, stem cells, antibody therapeutics, vaccines, medical diagnostics, cardiology, nephrology, angiology and protein fractionation. He assists local clients in developing commercially-focused patent strategies for the global and domestic markets. He also advises clients in contentious and non-contentious patent matters and has extensive experience in patent opposition proceedings.
Alex's PhD studies investigated the role of neurohormonal factors and inflammatory cytokines in the pathophysiology of experimental end stage renal failure. Upon completing his PhD, Alex accepted an invitation to pursue postdoctoral research in the area of cardiovascular disease at the Clinical Pharmacology Unit, Monash Medical School, Alfred Hospital. During this time, he collaborated extensively with research groups at BakerIDI and multinational pharmaceutical companies and has published his work internationally.
Alex gained his attorney qualifications in 2005 and recently joined the Biotechnology practice group of Davies Collison Cave after having worked for another large Australian IP firm. Alex is currently a Fellow of the IPTA Academy of Education and a member of various industry groups.
Alex has experience in handling IP matters relating to many areas of biotechnology, and has assisted local clients, including research institutes, universities and corporate entities, with patent drafting and local/overseas patent prosecution. He also has expertise in overseeing the prosecution of entire Australian and New Zealand patent portfolios for medium to large overseas biotechnology companies.
International Stem Cell Corporation v Comptroller General of Patents  EWHC 807 In October 2011, we reported on… more »
Changes will be introduced on 1 November 2012 that will see a reduction in some of the official filing and handling fees that… more »
The Full Federal Court has recently handed down its decision on Apotex's appeal against the earlier finding that its… more »
DCC continued its support of BioMelbourne Network initiatives by again hosting a lunch in the CEO luncheon forum series on… more »
The firm is pleased to announce the following new appointments: Dawn has joined the Trade Mark team located in our Sydney… more »